시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 기능성 자궁출혈 시장 보고서(2025년)
Dysfunctional Uterine Bleeding Global Market Report 2025
상품코드 : 1764306
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,527,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,434,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,341,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

기능성 자궁출혈 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 헬스케어 인프라의 확대, 낮은 침습 치료에 대한 수요 증가로 이어집니다.

월경장애의 유병률 상승은 향후 몇 년간의 기능성 자궁출혈 시장의 성장을 가속할 것으로 예측됩니다. 라이프스타일의 변화, 진단 방법의 개선에 의해 촉진되고 있습니다. 기능성 자궁출혈은 구조적 혹은 전신적인 질환과는 관련이 없는 비정상적인 자궁출혈 패턴을 검출하는 것으로, 월경 장애의 이해를 돕고, 정확한 진단과 치료를 서포트합니다. 예를 들어, 2023년 12월 영국에 본사를 둔 비영리 단체인 런던 트러스트는 영국에서 280만 명이 생리용품을 구입하는 데 어려움을 겪고 있으며, 이는 생리하는 사람 5명 중 1명에 해당하는 수치로 2022년 12%에서 2023년 21%로 크게 증가했다고 보고했습니다.

기능성 자궁출혈 시장의 주요 기업은 경구 GnRH 길항제와 같은 새로운 치료법의 개발에 주력하고 있으며, 호르몬 수준을 조정하여 월경 다량 출혈을 완화하는 효과적이고 비 수술적 선택을 제공합니다. 경구용 GnRH 길항제는 성선 자극 호르몬 방출 호르몬 수용체를 차단하고 에스트로겐 수치를 낮추며 침습적 시술 없이 자궁 근종을 축소하는 방식으로 작용합니다. 예를 들어 2024년 9월 영국 제약회 Theramex는 자궁 근종과 관련된 월경 다량 출혈을 치료하기 위해 1일 1회 투여된 경구 GnRH 길항제 Yselty(Linzagorix)를 출시했습니다. 따라서 유연한 투여가 가능합니다. 환자의 QOL을 유지하면서 증상을 효과적으로 완화하고 치료 중 임신성 온존을 지원합니다.전체적으로 이세르티는 자궁근종과 관련된 출혈을 관리하기 위한 혁신적인 전략입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Dysfunctional uterine bleeding (DUB) is characterized by abnormal uterine bleeding, typically caused by hormonal imbalances rather than structural issues. It primarily affects women of reproductive age and can manifest as heavy, prolonged, or irregular menstrual periods. DUB is diagnosed when no pelvic pathology, systemic illness, or pregnancy-related cause is identified. Treatment varies based on the severity and the patient's reproductive intentions.

The main categories of dysfunctional uterine bleeding are ovulatory and anovulatory. Ovulatory DUB occurs despite regular ovulation and often includes conditions like menorrhagia, polymenorrhagia, metrorrhagia, and dysmenorrhea. Diagnostic methods include hysteroscopy, ultrasonography, dilation and curettage, and endometrial biopsy. These techniques are used in managing menopause, dysfunctional uterine bleeding, endometrial cancer, contraception, hyperplastic precursor lesions, and other conditions. The primary end users include hospitals, clinics, diagnostic centers, and pharmaceutical companies.

The dysfunctional uterine bleeding market research report is one of a series of new reports from The Business Research Company that provides dysfunctional uterine bleeding market statistics, including the dysfunctional uterine bleeding industry global market size, regional shares, competitors with the dysfunctional uterine bleeding market share, detailed dysfunctional uterine bleeding market segments, market trends, and opportunities, and any further data you may need to thrive in the dysfunctional uterine bleeding industry. This dysfunctional uterine bleeding market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dysfunctional uterine bleeding market size has grown strongly in recent years. It will grow from $3.29 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be credited to the rising prevalence of hormonal imbalances, growing awareness of menstrual health, increased adoption of hormone therapy treatments, a higher number of women seeking gynecological care, and expanding research and development in women's health.

The dysfunctional uterine bleeding market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth projected for the forecast period is driven by the increasing prevalence of menstrual disorders, heightened awareness of women's health, greater adoption of advanced diagnostic techniques, expanding healthcare infrastructure, and a growing demand for minimally invasive treatments. Key trends during this period include progress in non-hormonal treatment options, improvements in diagnostic tools for menstrual disorders, development of minimally invasive surgical methods, innovations in menstrual health tracking technologies, and enhanced patient awareness and education initiatives.

The rising prevalence of menstrual disorders is expected to drive the growth of the dysfunctional uterine bleeding market in the coming years. Menstrual disorders encompass any irregularities or abnormalities in the menstrual cycle, such as changes in the frequency, duration, or volume of bleeding. This increase in menstrual disorders is fueled by greater awareness, lifestyle changes, and improved diagnostic methods that allow more cases to be identified and treated. Dysfunctional uterine bleeding aids in understanding menstrual disorders by detecting abnormal uterine bleeding patterns that are not linked to structural or systemic diseases, thereby supporting accurate diagnosis and treatment. For example, in December 2023, the Trust for London, a UK-based nonprofit, reported that 2.8 million people in the UK struggled to afford period products-equivalent to one in five menstruating individuals-and a significant rise from 12% in 2022 to 21% in 2023. Thus, the growing prevalence of menstrual disorders is contributing to the expansion of the dysfunctional uterine bleeding market.

Leading companies in the dysfunctional uterine bleeding market are concentrating on developing new treatments, such as oral GnRH antagonists, to offer effective, non-surgical options that reduce heavy menstrual bleeding by regulating hormone levels. An oral GnRH antagonist works by blocking gonadotropin-releasing hormone receptors, lowering estrogen levels, and shrinking uterine fibroids without the need for invasive procedures. For example, in September 2024, Theramex, a UK-based pharmaceutical firm, launched Yselty (linzagolix), an oral, once-daily GnRH antagonist aimed at treating heavy menstrual bleeding associated with uterine fibroids. This medication offers flexible dosing to better customize treatment for individual patients. It effectively alleviates symptoms while preserving patients' quality of life and supports fertility preservation during treatment. Overall, Yselty represents an innovative strategy for managing bleeding related to uterine fibroids.

In January 2025, Hologic Inc., a US-based medical technology company, acquired Gynesonics for $350 million. This acquisition adds the Sonata System to Hologic's portfolio-an innovative, incision-free treatment for uterine fibroids linked to heavy menstrual bleeding. The technology offers uterus-preserving options, strengthening Hologic's position in the abnormal uterine bleeding market. Gynesonics Inc., also based in the US, specializes in non-surgical medical devices that treat conditions causing dysfunctional uterine bleeding (DUB).

Major players in the dysfunctional uterine bleeding market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Medtronic plc, Boston Scientific Corporation, Smith & Nephew plc, Sun Pharmaceutical Industries Ltd., Hologic Inc., Sumitomo Pharma, Karl Storz SE & Co. KG, Cook Medical Incorporated, Gedeon Richter Plc, Lupin Ltd., Torrent Pharmaceuticals Ltd., CooperSurgical Inc., Ferring Pharmaceuticals SA, Minerva Surgical Inc., and Medgyn Products Inc.

North America was the largest region in the dysfunctional uterine bleeding market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dysfunctional uterine bleeding report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dysfunctional uterine bleeding market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dysfunctional uterine bleeding market includes revenues earned by entities by providing services such as emergency care services, fertility and reproductive health services, and telemedicine and virtual care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dysfunctional Uterine Bleeding Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dysfunctional uterine bleeding market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for dysfunctional uterine bleeding ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dysfunctional uterine bleeding market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Dysfunctional Uterine Bleeding Market Characteristics

3. Dysfunctional Uterine Bleeding Market Trends And Strategies

4. Dysfunctional Uterine Bleeding Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Dysfunctional Uterine Bleeding Growth Analysis And Strategic Analysis Framework

6. Dysfunctional Uterine Bleeding Market Segmentation

7. Dysfunctional Uterine Bleeding Market Regional And Country Analysis

8. Asia-Pacific Dysfunctional Uterine Bleeding Market

9. China Dysfunctional Uterine Bleeding Market

10. India Dysfunctional Uterine Bleeding Market

11. Japan Dysfunctional Uterine Bleeding Market

12. Australia Dysfunctional Uterine Bleeding Market

13. Indonesia Dysfunctional Uterine Bleeding Market

14. South Korea Dysfunctional Uterine Bleeding Market

15. Western Europe Dysfunctional Uterine Bleeding Market

16. UK Dysfunctional Uterine Bleeding Market

17. Germany Dysfunctional Uterine Bleeding Market

18. France Dysfunctional Uterine Bleeding Market

19. Italy Dysfunctional Uterine Bleeding Market

20. Spain Dysfunctional Uterine Bleeding Market

21. Eastern Europe Dysfunctional Uterine Bleeding Market

22. Russia Dysfunctional Uterine Bleeding Market

23. North America Dysfunctional Uterine Bleeding Market

24. USA Dysfunctional Uterine Bleeding Market

25. Canada Dysfunctional Uterine Bleeding Market

26. South America Dysfunctional Uterine Bleeding Market

27. Brazil Dysfunctional Uterine Bleeding Market

28. Middle East Dysfunctional Uterine Bleeding Market

29. Africa Dysfunctional Uterine Bleeding Market

30. Dysfunctional Uterine Bleeding Market Competitive Landscape And Company Profiles

31. Dysfunctional Uterine Bleeding Market Other Major And Innovative Companies

32. Global Dysfunctional Uterine Bleeding Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dysfunctional Uterine Bleeding Market

34. Recent Developments In The Dysfunctional Uterine Bleeding Market

35. Dysfunctional Uterine Bleeding Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기